How bioanalytical partners can accelerate high-complexity programs with small samples and high stakes

As rare disease pipelines expand and therapies become more advanced, sponsors face mounting complexity — from limited sample volumes to evolving regulatory requirements. This new report explores how mass spectrometry, microsampling and operational agility can drive success in these demanding settings.